Please wait while the formulary information is being retrieved.
ROBAXIN (methocarbamol)
- additional medication for tetanus
- muscle spasm
100 mg/mL injection solution
- Inject 10 milliliters (1 gram) by intramuscular route every 8 hours as needed
100 mg/mL injection solution
- Inject 10 milliliters (1 gram) by intramuscular route every 8 hours as needed
Muscle spasm
- Inject 10 milliliters (1 gram) by intravenous route every 8 hours as needed
- Inject 10 milliliters (1 gram) by intramuscular route every 8 hours as needed
Tetanus adjunct treatment
- Inject 10 milliliters (1,000 mg) by intravenous route every 6 hours until insertion of a nasogastric tube
- Inject 20 milliliters (2,000 mg) by intravenous route every 6 hours until insertion of a nasogastric tube
- None
Contraindicated
- None
Severe
Moderate
- None
- Kidney disease with reduction in GFR
Contraindicated
- None
Severe
Moderate
- Disease of liver
- Seizure disorder
ROBAXIN (methocarbamol)
- additional medication for tetanus
- muscle spasm
- Injection site sequelae
- Visual changes
- Blurred vision
- Diplopia
- Dizziness
- Drowsy
More Frequent
Severe
Less Severe
- Allergic dermatitis
- Bradycardia
- Conjunctivitis
- Drug fever
- Nasal congestion
- Pruritus of skin
- Skin rash
- Urticaria
- Dyspepsia
- Flushing
- Headache disorder
- Muscle weakness
- Nausea
- Nystagmus
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute cognitive impairment
- Anaphylaxis
- Angioedema
- Ataxia
- Dyskinesia
- Hypotension
- Jaundice
- Leukopenia
- Obstructive hyperbilirubinemia
- Syncope
- Thrombophlebitis
- Tonic clonic seizure
Less Severe
- Accidental fall
- Anticholinergic toxicity
- Insomnia
- Memory impairment
- Sedation
- Vertigo
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Methocarbamol (inj)
Limited use in treating tetanus in pediatrics. No established safety and efficacy.
- 1 Day – 18 Years
- Limited use in treating tetanus in pediatrics. No established safety and efficacy.
Methocarbamol
- Severity Level:
C
- Additional Notes: Limited data suggest an increased risk of congenital malformations
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Methocarbamol
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Methocarbamol (parenteral)
General- Not recommended in the elderly. Contraindicated in patients with renal impairment since the polyethylene glycol vehicle in the injectable product will accumulate and can cause acidosis. Neuro/Psych-May cause sedation, worsen cognitive impairment and increase fall risk.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | Y | N | N |
BEERS: Y HEDIS: N STOPP: N
No Known Risk
None
- None
| Muscle spasm | |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
| Tetanus adjunct treatment | |
| A33 | Tetanus neonatorum |
| A34 | Obstetrical tetanus |
| A35 | Other tetanus |
| 0-9 | A-Z |
|---|---|
| A33 | Tetanus neonatorum |
| A34 | Obstetrical tetanus |
| A35 | Other tetanus |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
Formulary Reference Tool